Medicines

For more than 140 years, we have worked tirelessly to develop and deliver trusted medicines that meet real needs.

The medicines listed below are available in Canada, unless otherwise noted. On this page you will find Product Monographs and Patient Medication Information (also known as Consumer Information). You will also find instructions on how to use our devices. Documents provided here are for informational use and for residents of Canada only.

If you are a customer and have questions about Lilly medicines, please call our Customer Response Centre at 1-888-545-5972 or submit your questions using this online form. If you are seeking medical advice, contact your health care provider.

: Adcirca® Product Monograph
Adcirca® Patient Medication Information

: Alimta® Product Monograph
Alimta® Patient Medication Information

Additional Information:

Please refer to the website of Drug Shortages Canada for information on the discontinuation of the 500 mg vial of Alimta® which took effect in March of 2021

: Bamlanivimab for injection received Notice of Authorization in accordance with the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19.

Bamlanivimab Product Monograph
Bamlanivimab Patient Medication Information

Additional Information:

Bamlanivimab Health Care Professional Letter (April 2021)
Bamlanivimab Health Care Professional Letter (December 2020)

Bamlanivimab Playbook: information for provincial, territorial and local public health programs in planning and implementing the use of bamlanivimab in response to COVID-19 (April 2021)

: Basaglar® Product Monograph
Basaglar® Patient Medication Information
Instructions for Use - Basaglar® KwikPen® (1 to 80 units)

: Baqsimi® Product Monograph
Baqsimi® Patient Medication Information

: Cialis® Product Monograph
Cialis® Patient Medication Information

Additional Information:
Cialis® Health Care Professional Letter (June 2006)
Cialis® Public Communication (June 2006)

: Cymbalta® Product Monograph
Cymbalta® Patient Medication Information

Additional Information:
Cymbalta® Health Care Professional Letter (January 2008)

: Cyramza® Product Monograph
Cyramza® Patient Medication Information

: Effient® Product Monograph
Effient® Patient Medication Information

Additional Information:
Please refer to the website of Drug Shortages Canada for information on the discontinuation of Effient® in Canada which took effect in February of 2020

Effient® Health Care Professional Letter (January 2020)
Effient® Health Care Professional Letter (January 2014)
Effient® Public Communication (January 2014)

: Emgality® Product Monograph
Emgality® Patient Medication Information
Instructions for Use - Emgality® 100 mg Single Dose Prefilled Syringe
Instructions for Use - Emgality® 120 mg Single Dose Prefilled Pen
Instructions for Use - Emgality® 120 mg Single Dose Prefilled Syringe

: Entuzity® Product Monograph
Entuzity® Patient Medication Information
Instructions for Use - Entuzity® KwikPen®

: Erbitux®∗ Product Monograph
Erbitux®∗ Patient Medication Information

: Evista® Product Monograph
Evista® Patient Medication Information

Additional Information:
Evista® Health Care Professional Letter (May 2006)
Evista® Public Communication (May 2006)

: Forteo® Product Monograph
Forteo® Patient Medication Information
Instructions for Use - Forteo® 2.4 mL Pen

: Glucagon Product Monograph
Glucagon Patient Medication Information

Additional Information:

Glucagon Patient Notification (Sept 2021)
Glucagon Public Notification (Sept 2021)
Glucagon Health Care Professional Notification (Sept 2021)
Glucagon Wholesaler Notification (Sept 2021)

: Glyxambi®+ Product Monograph
Glyxambi®+ Patient Medication Information

: Product Monograph Humalog®
Patient Medication Information - Humalog® Vials
Patient Medication Information - Humalog® Cartridges
Patient Medication Information - Humalog® KwikPen®
Patient Medication Information - Humalog® Junior KwikPen®
Instructions for Use - Humalog® KwikPen®
Instructions for Use - Humalog® Junior KwikPen®

: Humalog® 200 units/mL Product Monograph
Patient Medication Information - Humalog® 200 units/mL KwikPen®
Instructions for Use - Humalog® 200 units/mL KwikPen®

Additional Information:
Important safety information for HCPs and patients: Humalog® 200 units/mL KwikPen® (September 2015)

: Humalog® Mix25® Product Monograph
Patient Medication Information - Humalog® Mix25® Cartridges
Patient Medication Information - Humalog® Mix25® KwikPen®
Instructions for Use - Humalog® Mix25® KwikPen®

: Humalog® Mix50® Product Monograph
Patient Medication Information - Humalog® Mix50® Cartridges
Patient Medication Information - Humalog® Mix50® KwikPen®
Instructions for Use - Humalog® Mix50® KwikPen®

: Humatrope® Product Monograph
Humatrope® Patient Medication Information
Instructions for Use - HumatroPen® 6 mg
Instructions for Use - HumatroPen® 12 mg
Instructions for Use - HumatroPen® 24 mg
Instructions for using the Hidden Needle Cover with the Humatrope® Humatropen®

Additional Information:
Please refer to the website of Drug Shortages Canada for information on the discontinuation of the 5 mg vial of Humatrope®, which took effect in January of 2021.

: Humulin® Product Monograph
Patient Medication Information - Humulin® N Cartridges and KwikPen®
Patient Medication Information - Humulin® N Vials
Patient Medication Information - Humulin® R Cartridges and KwikPen®
Patient Medication Information - Humulin® R Vials
Patient Medication Information - Humulin® 30/70 Cartridges
Patient Medication Information - Humulin® 30/70 Vials
Instructions for Use - Humulin® N and Humulin® R KwikPen®

: Jardiance®+ Product Monograph
Jardiance®+ Patient Medication Information

Additional Information:
Important Safety Information for HCPs and patients: Jardiance® (May 2016)

: Jentadueto®+ Product Monograph
Jentadueto®+ Patient Medication Information

: Olumiant® Product Monograph
Olumiant® Patient Medication Information

: Prozac® Product Monograph
Prozac® Patient Medication Information

Additional Information:
Prozac® Health Care Professional Letter (May 2004)

: Retevmo™ Product Monograph
Retevmo™ Patient Medication Information

: Strattera® Product Monograph
Strattera® Patient Medication Information

Additional Information:
Strattera® Health Care Professional Letter (Oct 2011)
Strattera® Health Care Professional Letter (May 2006)
Strattera® Health Care Professional Letter (Sept 2005)
Strattera® Health Care Professional Letter (Feb 2005)
Strattera® Public Communication (Oct 2011)
Strattera® Public Communication (May 2006)
Strattera® Public Communication (Sept 2005)
Strattera® Public Communication (Feb 2005)

: Synjardy®+ Product Monograph
Synjardy®+ Patient Medication Information

: Taltz® Product Monograph
Taltz® Patient Medication Information
Instructions for Use - Taltz® Single-Use Prefilled Autoinjector
Instructions for Use - Taltz® Single-Use Prefilled Syringe

: Trajenta®+ Product Monograph
Trajenta®+ Patient Medication Information

: Trulicity® Product Monograph
Trulicity® Patient Medication Information
Instructions for Use - Trulicity® Single-Use Pen, 0.75 mg/0.5 mL
Instructions for Use - Trulicity® Single-Use Pen, 1.5 mg/0.5 mL

: Verzenio® Product Monograph
Verzenio® Patient Medication Information

: Zyprexa® Product Monograph
Zyprexa® Patient Medication Information

Additional Information:
Zyprexa® Health Care Professional Letter (Mar 2004)
Zyprexa® Public Communication (Mar 2004)

Re-usable Devices – Humalog® and Humulin® Family of Products

Instructions for Use - HumaPen® Luxura®
HumaPen® Luxura® pens are no longer distributed in Canada.

Instructions for Use - HumaPen Luxura® HD

Instructions for Use - HumaPen Savvio®

® Registered trademark owned by Eli Lilly and Company; used under license.

^TM Trademark owned by Eli Lilly and Company; used under license.

®* Registered trademark of ImClone LLC; used under license.

®+ Registered trademark of Boehringer Ingelheim International GmbH; used under license. Basaglar, Glyxambi, Jardiance, Jentadueto, Synjardy and Trajenta are part of the Boehringer Ingelheim–Lilly Alliance.

®± Registered trademark owned by R.P. Scherer Technologies, Inc., a Catalent Pharma Solutions Company